Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381678 | 1.00 | HTR2C (0.48) | HTR2CSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL30568002 | 1.00 | HTR2C (0.48) | HTR2CSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL21381934 | 1.00 | HTR2C (0.48) | HTR2CSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL21382293 | 1.00 | HTR2C (0.48) | HTR2CSLC6A2SLC6A4SLC6A3TACR1 | |
| Trifluoroacetic Acid SCHEMBL21381685 | 0.90 | OPRD1 (0.44) | — | |
| Trifluoroacetic Acid SCHEMBL30567963 | 0.90 | OPRD1 (0.44) | — | |
| SCHEMBL21382309 | 0.89 | HTR2C (0.52) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21381779 | 0.89 | HTR2C (0.52) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382077 | 0.89 | HTR2C (0.52) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30149783 | 0.89 | HTR2C (0.52) | HTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | HTR2C 3649/4885SLC6A2 4783/4885SLC6A4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.